Registration Momentum Builds Across the Oncology Pipeline
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: GlobeNewswire
VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The FDA's accelerated approval framework continues to deliver measurable population health gains, with a January 2026 analysis in Cancer Research Communications confirming that drugs cleared through the program improved real-world progression-free survival in 65% of solid tumor indications studied, with none performing worse than the existing standard of care[1]. That track record is fueling a concentrated push among clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types, as demonstrated by Oncolytics Biotech Inc. (NASDAQ: ONCY), Incyte (NASDAQ: INCY), Erasca, Inc. (NASDAQ: ERAS), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), and Acrivon Therapeutics, Inc. (NASDAQ: ACRV). The regulatory signal extends well beyond single approvals. In January 2026 alone, the FDA granted orphan drug designations for agents targeting gastrointestinal can
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- New Treatment Modalities Are Reaching Cancers That Resisted Everything Else [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep [Yahoo! Finance]Yahoo! Finance
- Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- $207B Market Shift: The Race for Fast Track Approval in Oncology [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- The $71 Billion Cancer Shift: Why The FDA Is Speeding UpGlobeNewswire
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 2/13/26 - Form 4
- 2/13/26 - Form 4
- 2/13/26 - Form 4
- ONCY's page on the SEC website